(CNN) — A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed that ...

Add Yahoo as a preferred source to see more of our stories on Google. A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...

Did you know that there is a medication referred to as the birth control pill for HIV? HIV Pre-Exposure Prophylaxis (PrEP) is a pill that may cause a revolution in HIV prevention. If taken daily, ...

A patient recently asked me this during his visit to an HIV clinic in the Dominican Republic. He was there to refill his monthly prescription for pre-exposure prophylaxis (PrEP), a daily pill that ...